The use of biomarkers in the diagnosis and management of emergency medical conditions


  • Ahmed Amin Aljefri Department of Emergency Medicine, Al Thager Hospital, Jeddah, Saudi Arabia
  • Mazen Saud Alharthi College of Medicine, Taif University, Taif, Saudi Arabia
  • Farhan Mufarreh Almadari Department of Otolaryngology, Khamis Mushait Maternity and Children Hospital, Khamis Mushait, Saudi Arabia
  • Hassan Abdualmohsin Alazwari Department of General Surgery, King Faisal Hospital, Mecca, Saudi Arabia
  • Zafer Ali Alshahrani Department of Emergency Medicine, Armed Forces Hospital Southern Region, Khamis Mushait, Saudi Arabia
  • Abdullah Abdulelah Alanazi Department of Emergency Medicine, Al Iman General Hospital, Riyadh, Saudi Arabia
  • Afnan Qasem Al Gadani My Modern Clinic, Sabt Al Alaya, Saudi Arabia
  • Ahmed Ali Aljawad College of Medicine, Medical University of Warsaw, Warsaw, Poland
  • Faris Mohammed Qattan College of Medicine, Taif University, Taif, Saudi Arabia
  • Abdulrahman Hassan Shuraym College of Medicine, Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia
  • Aisha Nour Almutary College of Medicine, Almaarefa University, Riyadh, Saudi Arabia



Biomarkers, Emergency medicine, Cardiovascular emergencies, Procalcitonin, Artificial intelligence


The use of biomarkers in emergency situations represents a change in modern healthcare. This review examines their impact in emergencies focusing on how they improve the accuracy of diagnoses, provide insights into prognosis and aid in treatment decisions. Notably troponins (I and T) are effective in diagnosing myocardial infarction enabling targeted interventions and risk assessment for cardiovascular emergencies. In cases of sepsis procalcitonin helps distinguish infections and influences decisions about therapy, which is crucial for global efforts against resistance. S100B, a biomarker used in emergencies assists in prioritizing cases of brain injury. To prevent harm, serum markers like creatinine and cystatin C guide interventions for hepatic emergencies. For trauma and hematological emergencies D dimer and lactate provide prognostic information. Ongoing research is exploring biomarkers well as the integration of artificial intelligence offering promising advancements for the future. The clinical significance of biomarkers highlights a commitment to approaches that contribute to the ever-evolving field of emergency medicine and ultimately enhance patient care.


Bodaghi A, Fattahi N, Ramazani A. Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases. Heliyon. 2023;9(2):e13323.

Christenson E, Christenson RH. The role of cardiac biomarkers in the diagnosis and management of patients presenting with suspected acute coronary syndrome. Ann Lab Med. 2013;33(5):309-18.

Aspromonte N, Zaninotto M, Aimo A, Fumarulo I, Plebani M, Clerico A. Measurement of Cardiac-Specific Biomarkers in the Emergency Department: New Insight in Risk Evaluation. Int J Mol Sci. 2023;24(21):15998.

Ontario Health (Quality). Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure: A Health Technology Assessment. Ont Health Technol Assess Ser. 2021;21(2):1-125.

Palazzuoli A, Gallotta M, Quatrini I, Nuti R. Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure. Vasc Health Risk Manag. 2010;6:411-8.

Samuel MS, Latha R, Kavitha K, Sivasubramanian V. A study on biomarkers of sepsis and potential role of procalcitonin and ferritin marker in diagnosis, prognosis and treatment. J Family Med Prim Care. 2022;11(6):2608-12.

Creamer AW, Kent AE, Albur M. Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy. Breathe (Sheff). 2019;15(4):296-304.

Oris C, Kahouadji S, Durif J, Bouvier D, Sapin V. S100B, Actor and Biomarker of Mild Traumatic Brain Injury. Int J Mol Sci. 2023;24(7):6602.

Goyal A, Failla MD, Niyonkuru C, Amin K, Fabio A, Berger RP, Wagner AK. S100b as a prognostic biomarker in outcome prediction for patients with severe traumatic brain injury. J Neurotrauma. 2013;30(11):946-57.

Calcagnile O, Undén L, Undén J. Clinical validation of S100B use in management of mild head injury. BMC Emerg Med. 2012;12:13.

Gunawan PI, Saharso D, Sari DP. Correlation of serum S100B levels with brain magnetic resonance imaging abnormalities in children with status epilepticus. Korean J Pediatr. 2019;62(7):281-5.

Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol. 2008;48:463-93.

Brazzelli M, Aucott L, Aceves-Martins M, Robertson C, Jacobsen E, Imamura M, et al. Biomarkers for assessing acute kidney injury for people who are being considered for admission to critical care: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2022;26(7):1-286.

Bolvardi E, Malmir J, Reihani H, Hashemian AM, Bahramian M, Khademhosseini P, et al. The role of lactate clearance as a predictor of organ dysfunction and mortality in patients with severe sepsis. Mater Sociomed. 2016;28(1):57-60.

Lee SM, An WS. New clinical criteria for septic shock: serum lactate level as new emerging vital sign. J Thorac Dis. 2016;8(7):1388-90.

Stokes NR, Dietz BW, Liang JJ. Cardiopulmonary laboratory biomarkers in the evaluation of acute dyspnea. Open Access Emerg Med. 2016;8:35-45.

Wang XY, Zhang F, Zhang C, Zheng LR, Yang J. The Biomarkers for Acute Myocardial Infarction and Heart Failure. Biomed Res Int. 2020;2020:2018035.

Frangogiannis NG. Biomarkers: hopes and challenges in the path from discovery to clinical practice. Transl Res. 2012;159(4):197-204.

Anoop TC. Biomarkers of Diseases: Their Role in Emergency Medicine. In: Nagehan Ersoy T, eds. Neurodegenerative Diseases. Rijeka: IntechOpen; 2020.

Nayer J, Aggarwal P, Galwankar S. Utility of point-of-care testing of natriuretic peptides (brain natriuretic peptide and n-terminal pro-brain natriuretic peptide) in the emergency department. Int J Crit Illn Inj Sci. 2014;4(3):209-15.

Sweeney C, Ryan F, Ledwidge M, Ryan C, McDonald K, Watson C, et al. Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure. Cochrane Database Syst Rev. 2019;10(10):CD013015.

Hajar R. Evolution of Myocardial Infarction and its Biomarkers: A Historical Perspective. Heart Views. 2016;17(4):167-72.




How to Cite

Aljefri, A. A., Alharthi, M. S., Almadari, F. M., Alazwari, H. A., Alshahrani, Z. A., Alanazi, A. A., Al Gadani, A. Q., Aljawad, A. A., Qattan, F. M., Shuraym, A. H., & Almutary, A. N. (2023). The use of biomarkers in the diagnosis and management of emergency medical conditions. International Journal Of Community Medicine And Public Health, 11(1), 521–525.



Review Articles